- Advertisement -
Wednesday, September 23, 2020
32.7 C
Delhi
Home Latest News ASTRAZENECA HALTS CORONAVIRUS VACCINE TRIAL AFTER VOLUNTEER DEVELOPS ‘UNEXPECTED’ ILLNESS

ASTRAZENECA HALTS CORONAVIRUS VACCINE TRIAL AFTER VOLUNTEER DEVELOPS ‘UNEXPECTED’ ILLNESS

In a significant development, pharmaceutical company AstraZeneca on Tuesday (September 8) said that it “voluntarily paused” the phase 3 clinical human trials of its vaccine candidate ‘Covishield’ after one of the volunteers got ill. It is to be noted that AstraZeneca is developing this vaccine in collaboration with University of Oxford.

Image courtesy Zee News

In a significant development, pharmaceutical company AstraZeneca on Tuesday (September 8) said that it “voluntarily paused” the phase 3 clinical human trials of its vaccine candidate ‘Covishield’ after one of the volunteers got ill. It is to be noted that AstraZeneca is developing this vaccine in collaboration with University of Oxford.

“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow a review of safety data by an independent committee,” the pharma major said in a statement. 

It is learnt that a volunteer developed unexpected sickness during trial of the vaccine for reasons not yet known. AstraZeneca, however, noted that the volunteer would soon recover.

AstraZeneca said it was a “routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”

“We are working to expedite the review of the single event to minimize any potential impact on the trial timeline,” the statement added.

Notably, Pune-based Serum Institute of India, which is handling the Phase 3 trials of AstraZeneca’s vaccine in India, is preparing a list of volunteers who will be administered the vaccine shots under the National Immunization Programme (NIP).

It is learnt that 1,600 participants of more than or equal to 18 years of age will be enrolled in the study. Serum Institute of India will conduct the drive on 17 sites in India.

News Credit Zee News

- Advertisement -

Subscribe to our newsletter

To be updated with all the latest news,

- Advertisement -

Stay Connected

8,000FansLike
2,458FollowersFollow
61,453SubscribersSubscribe

Must Read

NCB SUMMONS DEEPIKA PADUKONE, SHRADDHA KAPOOR, SARA ALI KHAN, RAKUL PREET SINGH IN DRUGS CASE

Today, the NCB probed Sushant’s former manager and KWAN employee Jaya Saha, director of the management agency, producer Madhu Mantena. 
- Advertisement -

US, UAE EYE DECEMBER GOAL TO AGREE ON F-35 DEAL, SAY SOURCES

Sources close to the negotiations said the goal is to have a letter of agreement in place in time for UAE National...

IMD PREDICTS VERY HEAVY RAINFALL IN WEST BENGAL, ASSAM, UTTAR PRADESH AND BIHAR OVER NEXT FEW DAYS

A low-pressure area lies over central parts of west Madhya Pradesh and neighbourhood with associated cyclonic circulation extending up to mid-tropospheric levels.

CORONAVIRUS CAME FROM A LAB ON PURPOSE, SAYS CHINESE VIROLOGIST DR LI-MENG YAN

On being asked whether she thought that the Chinese government could influence studies and research on COVID-19, Dr Li-Meng Yan said “Of...

Related News

NCB SUMMONS DEEPIKA PADUKONE, SHRADDHA KAPOOR, SARA ALI KHAN, RAKUL PREET SINGH IN DRUGS CASE

Today, the NCB probed Sushant’s former manager and KWAN employee Jaya Saha, director of the management agency, producer Madhu Mantena. 

US, UAE EYE DECEMBER GOAL TO AGREE ON F-35 DEAL, SAY SOURCES

Sources close to the negotiations said the goal is to have a letter of agreement in place in time for UAE National...

IMD PREDICTS VERY HEAVY RAINFALL IN WEST BENGAL, ASSAM, UTTAR PRADESH AND BIHAR OVER NEXT FEW DAYS

A low-pressure area lies over central parts of west Madhya Pradesh and neighbourhood with associated cyclonic circulation extending up to mid-tropospheric levels.

CORONAVIRUS CAME FROM A LAB ON PURPOSE, SAYS CHINESE VIROLOGIST DR LI-MENG YAN

On being asked whether she thought that the Chinese government could influence studies and research on COVID-19, Dr Li-Meng Yan said “Of...

RUSSIA TO REGISTER SECOND CORONAVIRUS VACCINE BY OCTOBER 15

The vaccine has been developed by Siberia’s Vector Institute, which completed early-stage human trials of the vaccine last week.
- Advertisement -